Table 1. Description of studies included in the meta-analysis of association between toxoplasmosis and epilepsy.
| Reference | Study | Source 1 | Definition | Source 2 | Matching* | Measure of exposure |
|---|---|---|---|---|---|---|
| Potasman (Israel) | CC | Hospital | Other | Hospital | Unspecified | ELISA IgG (Tox-G EAI diagnostic kit, Abbott lab) |
| Stommel (USA) | CC | GP | ILAE | Community | Unspecified | ELISA IgG |
| Yazar (Turkey) | CC | Hospital | ILAE | Volunteers | Yes | ELISA IgG (ELISA Kit EUROIMMUN) |
| Akyol (Turkey) | CC | Hospital | ILAE | Volunteers | Yes | in house ELISA IgG kit |
| Zibaei (Iran) | CC | GP | ILAE | Community | Yes | Diaplus Inc, Toxo IgG, USA |
| Ngugi (SSA) | CC | GP | WHO | Community | Yes | IgG-ELISA, Genesis Diagnostics |
CC: Case-control; GP: General population; ELISA: enzyme-linked immunosorbent assay; IgG: Immunoglobulin G; ILAE: International league against epilepsy; SSA: Sub-saharan Africa, WHO: World health organization,
*matching is by age and gender alone
Study: Study type; source 1: source of epilepsy cases; source 2: source of non-epilepsy controls; definition: definition of epilepsy; Other: clinical history by pediatric neurologist, repeated electroencephalography and computed tomography of the brain